Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 42

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 42
---
 of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There
is no required minimum number of securities or amount of proceeds that must be sold as a condition to completion of this offering. Because
there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent
fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may
sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors
in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to fund for our operations
as described in the “Use of Proceeds” section herein. Thus, we may not raise the amount of capital we believe is required
for our operations in the short-term and even if we raise the maximum offering amount in this public offering, we will need to raise additional
funds in the future, which may not be available or available on terms acceptable to us. For more on the risks related to our funding requirements,
see “Risk Factors—Risks Related to Our Business—Our financial statements have been prepared on a going-concern basis and our continued operations are in doubt.”

The Warrants are speculative in nature.

The Series A-1 Warrants, Series A-2 Warrants and
Pre-Funded Warrants offered in this offering do not confer any rights of common stock ownership on their holders, such as voting rights
or the right to receive dividends, but rather merely represent the right to acquire shares of our common stock at a fixed price for a
limited period of time. Specifically, effective on the Initial Exercise Date, holders of the Series A-1 Warrants and Series A-2 Warrants
may exercise their right to acquire the common stock and pay an assumed exercise price of $2.455 per share, prior to the fifth
year anniversary and 18 month anniversary, respectively, from the Initial Exercise Date, after which date any unexercised Warrants
will expire and have no further value. Commencing on the date of issuance, holders of the Pre-Funded Warrants may exercise their right
to acquire shares of common stock and pay an exercise price of $0.0001 per share. The Pre-Funded Warrants have no expiration date.

Holders of the Warrants and the Pre-Funded Warrants will